Table 2.
Omalizumab dosages (mg)
| Baseline serum IgE level (kU/L) | Weight (kg) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≥20–25 | > 25–30 | > 30–40 | > 40–50 | > 50–60 | > 60–70 | > 70–80 | > 80–90 | > 90–125 | > 125–150 | |
| ≥30–100 | 75# | 75# | 75# | 150# | 150# | 150# | 150# | 150# | 300# | 300# |
| > 100–200 | 150# | 150# | 150# | 300# | 300# | 300# | 300# | 300# | 450# | 600# |
| > 200–300 | 150# | 150# | 225# | 300# | 300# | 450# | 450# | 450# | 600# | 375## |
| > 300–400 | 225# | 225# | 300# | 450# | 450# | 450# | 600# | 600# | 450## | 525## |
| > 400–500 | 225# | 300# | 450# | 450# | 600# | 600# | 375## | 375## | 525## | 600## |
| > 500–600 | 300# | 300# | 450# | 600# | 600# | 375## | 450## | 450## | 600## | |
| > 600–700 | 300# | 225## | 450# | 600# | 375## | 450## | 450## | 525## | ||
| > 700–800 | 225## | 225## | 300## | 375## | 450## | 450## | 525## | 600## | ||
| > 800–900 | 225## | 225## | 300## | 375## | 450## | 525## | 600## | |||
| > 900–1000 | 225## | 300## | 375## | 450## | 525## | 600## | ||||
| > 1000–1100 | 225## | 300## | 375## | 450## | 600## | |||||
| > 1100–1200 | 300## | 300## | 450## | 525## | 600## | |||||
| > 1200–1300 | 300## | 375## | 450## | 525## | ||||||
| > 1300–1500 | 300## | 375## | 525## | 600## | ||||||
IgE, immunoglobulin E. #, omalizumab was administrated every 4 weeks. ##, omalizumab was administrated every 2 weeks.